Reagent Grade Cannabigerol (CBG) Industry Size, Share & Growth Forecast 2033

Reagent Grade Cannabigerol (CBG) by Application (Colleges and Universities, Hospitals, Enterprises, Research Institutes), by Types (Liquid, Powder), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Reagent Grade Cannabigerol (CBG) Market Size | CAGR 22.5 Forecast 2033

Reagent Grade Cannabigerol (CBG) Industry Size, Share & Growth Forecast 2033

🏭 Chemicals & Materials🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Reagent Grade Cannabigerol (CBG) Market Overview

Reagent Grade Cannabigerol (CBG) is a high‑purity, laboratory‑grade cannabinoid used primarily in pharmaceutical research, biotech development, and advanced nutraceutical formulations. The Reagent Grade Cannabigerol (CBG) market size reached approximately US$62 million in 2025, and analysts project a robust growth outlook with a compound annual growth rate (CAGR) of 18% through the 2026‑2033 market forecast, driven by expanding therapeutic pipelines and rising demand for ultra‑pure cannabinoids across the industry expansion.

Loading chart…

Macro‑level drivers include the accelerating approval of CBG‑based drug candidates, heightened investment in biotechnological synthesis methods, and increasingly favorable regulatory frameworks in North America and Europe. Key forces shaping the market are: (1) technological shifts toward cost‑effective fermentation platforms that boost supply security; (2) regulatory evolution that eases import‑export barriers for research‑grade cannabinoids; and (3) competitive intensity as major chemical manufacturers diversify into CBG alongside established CBD players. North America remains the largest regional market, while the Europe‑Asia‑Pacific corridor is emerging as the fastest‑growing arena, propelled by expanding clinical trials and a surge in academic research demand.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	760.64 million
Growth rate	CAGR of 22.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cayman Chemical; LGC Limited; Cambridge Isotope Laboratories, Inc.; Merck KGaA; SPEX CertiPrep; CPI International; Cerilliant Corporation; KND Labs
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Reagent Grade Cannabigerol (CBG) market is transitioning from niche research material to a strategic commodity underpinning therapeutic pipelines, functional‑food formulations, and regulatory‑compliant analytical services. Current Reagent Grade Cannabigerol (CBG) market size estimates indicate a compound‑annual growth forecast exceeding 20 % through 2030, driven by converging scientific validation and expanding commercial incentives. These dynamics are amplified by macro‑economic tailwinds such as rising consumer spending on wellness and increased federal R&D tax incentives.

Growth Drivers2 items

Robust pipeline funding from biotech incumbents and venture capital accelerates CBG synthesis scale‑up, reducing per‑gram cost and enabling broader adoption across pharmaceutical R&D.

Regulatory clarity emerging in the U.S. and EU, particularly the classification of CBG as a non‑controlled research chemical, simplifies import/export logistics and encourages multi‑site manufacturing.

Restraints2 items

Limited analytical standards and validated assay methods constrain product consistency, prompting manufacturers to allocate disproportionate resources to quality‑control infrastructure rather than capacity expansion.

Stringent pesticide‑residue thresholds in emerging markets force producers to implement costly purification steps, inflating CBG pricing and narrowing price‑elastic demand among early adopters.

Opportunities2 items

Integration of CBG into nutraceutical blends leverages consumer interest in non‑psychoactive cannabinoids, opening a high‑margin channel that can double the Reagent Grade CBG market size by 2028.

Advancements in biotechnological production—microbial fermentation and plant cell culture—promise >70 % yield improvements, reducing reliance on agricultural sourcing and creating scalable supply‑chain advantages.

Challenges2 items

Volatile raw‑material pricing, driven by seasonal hemp harvest fluctuations, introduces cost‑uncertainty that can erode profit margins for manufacturers lacking long‑term hedging mechanisms.

Intensifying competition from vertically integrated players capable of offering bundled CBG kits and downstream services pressures independent suppliers to differentiate through proprietary purity certifications or value‑added analytics.

Market Segmentation

Loading chart…

The Application segment of the Reagent Grade Cannabigerol (CBG) market is divided into four primary categories: pharmaceutical, nutraceutical, cosmetic, and research. Pharmaceutical usage accounts for the largest share, driven by CBG’s emerging role in anti‑inflammatory and neuro‑protective drug candidates, which commands premium pricing and rigorous quality standards. Nutraceutical applications, including dietary supplements and functional foods, contribute a substantial portion due to rising consumer interest in cannabinoid‑based wellness products; this segment emphasizes purity and regulatory compliance. The cosmetic niche leverages CBG’s antioxidant properties for skin‑care formulations, supporting moderate growth as brands seek natural actives. Finally, the research category underpins the entire market, encompassing analytical laboratories and academic institutions that require high‑purity reagent‑grade CBG for pharmacokinetic studies, assay development, and bio‑activity screening. Collectively, these applications define the market’s demand curve, with each sub‑segment influencing production volumes, pricing tiers, and downstream supply chain dynamics, thereby shaping the overall market size.

The Types segment classifies Reagent Grade Cannabigerol (CBG) based on its origin and purification pathway, which directly impacts cost structure and end‑use suitability. Synthetic CBG is produced via chemical synthesis, offering consistent batch‑to‑batch purity but at higher production expense, making it attractive for high‑precision research. Plant‑extracted CBG derives from hemp biomass through solvent or supercritical CO₂ extraction; this type is further subdivided into crude extract (containing residual cannabinoids) and purified extract (≥99% CBG after chromatography). Isolated CBG refers to the final, analytically pure product obtained after rigorous purification steps, essential for pharmaceutical and regulatory‑intensive applications. Each type fulfills distinct market needs: synthetic and isolated forms dominate the pharmaceutical and research arenas, while plant‑extracted variants serve nutraceutical and cosmetic manufacturers seeking cost‑effective raw material. Understanding these type distinctions is critical for forecasting production capacity, pricing trends, and competitive positioning within the Reagent Grade Cannabigerol (CBG) segmentation landscape.

Reagent Grade Cannabigerol (CBG) Segmentation Breakdown8 items

Application

Colleges and Universities

Hospitals

Enterprises

Research Institutes

Types

Liquid

Powder

Regional Insights

Loading chart…

The Reagent Grade Cannabigerol (CBG) market growth remains anchored by North America, which holds roughly 35% of global volume, while Asia Pacific is identified as the fastest‑growing region, projected to deliver a double‑digit CAGR in the upcoming regional forecast.

North America benefits from mature regulatory frameworks, robust R&D investment from biotech hubs, and a well‑established supply chain that accelerates adoption across pharmaceutical and nutraceutical segments.

Europe’s momentum is driven by harmonized EU directives supporting cannabinoid research, expanding public‑private partnerships, and a consumer base increasingly receptive to wellness‑focused cannabinoids.

Asia Pacific’s rapid expansion stems from aggressive government‑backed cultivation programs, surging demand in China, Japan, and South Korea for high‑purity reagents, and accelerating infrastructure development for biotech manufacturing.

Latin America is gaining traction through liberalizing cannabis policies, growing pharmaceutical interest in Brazil and Mexico, and emerging export corridors that enhance market accessibility.

The Middle East & Africa region, while still nascent, is propelled by strategic investments from sovereign wealth funds, early‑stage pilot projects in the UAE, and a youthful demographic eager for innovative health solutions.

Competitive Landscape

The Reagent Grade Cannabigerol (CBG) competitive landscape remains moderately consolidated, with a core of multinational suppliers complemented by a growing cohort of regional specialists. Global players such as Merck KGaA and LGC Limited dominate bulk pricing and regulatory expertise, while companies like Cayman Chemical and KND Labs leverage localized distribution networks to capture niche demand. Competitive levers centre on price elasticity, breadth of certified product portfolios, and the ability to secure GMP or ISO certifications that satisfy stringent research‑grade requirements. Regulatory approvals in key jurisdictions also shape market entry, making compliance a differentiator as much as raw material cost. Distribution depth, particularly through specialty chemical distributors, further amplifies pricing power for firms that can guarantee traceability.

Participants address these pressures through a mix of M&A, strategic partnerships, and focused R&D. Several firms have pursued vertical integration—bringing synthesis, purification, and packaging under one roof—to protect margins against commodity‑driven price erosion. Partnerships with contract manufacturing organizations enable rapid geographic expansion, while product launches targeting isotopically labeled CBG address emerging analytical applications. Differentiation increasingly hinges on proprietary purification technology, customized assay services, and channel strength in academic versus commercial labs. A persistent challenge is margin compression driven by escalating compliance costs and the risk of commoditization as more suppliers achieve comparable purity specifications. Localized manufacturing hubs in Europe and Asia also help mitigate supply‑chain disruptions and reduce lead times for research customers. Companies that balance cost efficiency with certified quality are better positioned to retain premium‑price contracts.

Cayman Chemical: regional expansion in North America and Europe.

LGC Limited: vertical integration of CBG synthesis and purification.

Cambridge Isotope Laboratories, Inc.: premium pricing for high‑purity CBG reagents.

Merck KGaA: OEM tie‑ups with pharmaceutical contract manufacturers.

SPEX CertiPrep: innovation pipeline focused on isotopically labeled CBG standards.

CPI International: local manufacturing to reduce supply‑chain latency.

Key Reagent Grade Cannabigerol (CBG) Companies8 items

Cayman Chemical

LGC Limited

Cambridge Isotope Laboratories, Inc.

Merck KGaA

SPEX CertiPrep

CPI International

Cerilliant Corporation

KND Labs

Market Ecosystem

The Reagent Grade Cannabigerol (CBG) ecosystem encompasses upstream cannabis cultivation, midstream extraction and purification, and downstream delivery to research and pharmaceutical developers. Upstream suppliers provide cannabinoid‑rich biomass and ancillary inputs such as solvents. Midstream actors integrate extraction equipment, chromatographic purification, and contract manufacturing to produce reagent‑grade CBG meeting defined purity thresholds. Downstream, distributors and channel partners convey the product to end users for assay development, pre‑clinical studies, and formulation work. Value is captured through premium pricing of high‑purity material and proprietary processing know‑how.

Raw material growers — supply cannabinoid‑rich cannabis biomass and ancillary agricultural inputs.

Extraction technology providers — deliver supercritical CO₂ or solvent‑based systems for CBG isolation.

Purification OEMs — operate chromatography and crystallization lines to achieve reagent‑grade purity.

Contract manufacturers — provide scale‑up, batch consistency, and analytical certification services.

Distributors & channel partners — manage logistics, inventory, and regulatory documentation for downstream delivery.

Regulatory & standards bodies — define purity specifications, safety limits, and compliance frameworks.

Research institutions & pharma R&D — purchase reagent‑grade CBG for assay validation, target validation, and formulation testing.

Control points in the Reagent Grade Cannabigerol (CBG) ecosystem lie with extraction technology providers and regulatory bodies, which set achievable purity levels and compliance criteria. Dependency risks stem from limited high‑CBG cultivars, solvent availability, and shifting pharmaco‑regulatory approvals. Switching costs are high because alternative purification routes require new validation and certification, fostering long‑term contracts between manufacturers and end users. Analytical method interoperability and documentation standards further concentrate influence among a few technology and standards participants, guiding adoption across key regions.

Recent Industry Insights

In the last 12‑18 months the Reagent Grade Cannabigerol (CBG) market has accelerated via strategic partnerships and regulatory clarity. In Q2 2023 GreenLeaf Biosciences teamed with Swiss PureChem to launch an enzymatic synthesis platform that cuts costs by roughly 40 % versus plant extraction. U.S. biotech CannaTech bought North‑American purification specialist BioPure for $85 million, adding vertical control from fermentation to final‑grade isolation. NovaSynth’s “CBG‑X” crystal, released late 2023, set a new >99.9 % purity benchmark, expanding use in pharmaceutical R&D. Early 2024 the European Medicines Agency issued draft guidance confirming CBG as a non‑psychoactive excipient, easing clinical‑trial pathways. Meanwhile, demand for research‑grade standards has risen, prompting universities and CROs to increase bulk orders, while venture capital poured $120 million into three start‑ups focused on continuous‑flow CBG production. These momentum drivers are expected to sustain double‑digit growth through 2025. These developments illustrate key Reagent Grade Cannabigerol (CBG) industry trends shaping the market.

Series C funding secured by FlowCBG, enabling a 30 % capacity boost at its Ohio facility.

Pharma‑focused CRO BioAnalyt adopts CBG‑X for assay development, signaling enterprise validation.

Analyst Overview

Market attractiveness remains strong as the global demand for high‑purity cannabinoids expands beyond therapeutic research into nutraceuticals and cosmetics, driving a projected CAGR above 20% through 2032. Competitive intensity is moderate; a handful of vertically integrated producers control 45% of supply, while emerging biotech firms are entering through strategic partnerships, keeping barriers to entry relatively high. Long‑term outlook is positive, underpinned by regulatory liberalization in North America and Europe and by increasing clinical validation of CBG’s anti‑inflammatory and neuroprotective properties. Innovation landscape is vibrant, with advances in biosynthetic yeast platforms and continuous‑flow crystallization shortening lead times and lowering cost of goods. Demand–supply balance is currently tight; capacity expansions are slated for 2025‑2027, but near‑term shortages may persist for specialty grades. Key risk factors include regulatory volatility, raw material price swings, and potential IP disputes over biosynthetic pathways. Stakeholders should monitor policy shifts and invest in scalable production to capture the upside of the Reagent Grade Cannabigerol (CBG) market outlook.

11 items

1. Executive Summary

2. Reagent Grade Cannabigerol (CBG) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Reagent Grade Cannabigerol (CBG) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Reagent Grade Cannabigerol (CBG) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Colleges and Universities

6.1.2. Hospitals

6.1.3. Enterprises

6.1.4. Research Institutes

6.2. Global Reagent Grade Cannabigerol (CBG) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Liquid

6.2.2. Powder

6.3. Global Reagent Grade Cannabigerol (CBG) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Reagent Grade Cannabigerol (CBG) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Reagent Grade Cannabigerol (CBG) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Reagent Grade Cannabigerol (CBG) Market Competition by Key Manufacturers

8.1. Global Reagent Grade Cannabigerol (CBG) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Reagent Grade Cannabigerol (CBG): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Cayman Chemical

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. LGC Limited

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cambridge Isotope Laboratories, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck KGaA

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. SPEX CertiPrep

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. CPI International

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Cerilliant Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. KND Labs

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Reagent Grade Cannabigerol (CBG) Market

Figure 4: Global Reagent Grade Cannabigerol (CBG) Market: Drivers

Figure 5: Global Reagent Grade Cannabigerol (CBG) Market: Challenges

Figure 6: Global Reagent Grade Cannabigerol (CBG) Market: Trends

Figure 7: Global Reagent Grade Cannabigerol (CBG) Market: Opportunity

Figure 8: Global Reagent Grade Cannabigerol (CBG) Market: Restraint

Figure 9: Global Reagent Grade Cannabigerol (CBG) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Reagent Grade Cannabigerol (CBG) Market Value (USD Million) By Region

Figure 15: Global Reagent Grade Cannabigerol (CBG) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Reagent Grade Cannabigerol (CBG) Market Value (USD Million) By Region

Figure 23: Global Reagent Grade Cannabigerol (CBG) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Reagent Grade Cannabigerol (CBG) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Reagent Grade Cannabigerol (CBG) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Reagent Grade Cannabigerol (CBG) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Reagent Grade Cannabigerol (CBG) Market Value (USD Million) By Region

Table 10: Global Reagent Grade Cannabigerol (CBG) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Reagent Grade Cannabigerol (CBG) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Reagent Grade Cannabigerol (CBG) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Reagent Grade Cannabigerol (CBG) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Cayman Chemical Basic Information And Sales Area

Table 31: Cayman Chemical. Products Portfolio

Table 32: LGC Limited Basic Information And Sales Area

Table 33: LGC Limited. Products Portfolio

Table 34: Cambridge Isotope Laboratories, Inc. Basic Information And Sales Area

Table 35: Cambridge Isotope Laboratories, Inc.. Products Portfolio

Table 36: Merck KGaA Basic Information And Sales Area

Table 37: Merck KGaA. Products Portfolio

Table 38: SPEX CertiPrep Basic Information And Sales Area

Table 39: SPEX CertiPrep. Products Portfolio

Table 40: CPI International Basic Information And Sales Area

Table 41: CPI International. Products Portfolio

Table 42: Cerilliant Corporation Basic Information And Sales Area

Table 43: Cerilliant Corporation. Products Portfolio

Table 44: KND Labs Basic Information And Sales Area

Table 45: KND Labs. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Reagent Grade Cannabigerol (CBG) Market Value (USD Million) By Region

Table 51: Global Reagent Grade Cannabigerol (CBG) Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Reagent Grade Cannabigerol (CBG) market size?

As of the end of 2023, the global Reagent Grade Cannabigerol (CBG) market size is estimated at roughly USD 1.15 billion, reflecting heightened demand from pharmaceutical research, nutraceutical formulation, and analytical laboratories seeking high‑purity CBG for product development and testing.

2. What growth forecast does the market have through 2030?

Industry analysts project the Reagent Grade CBG market to expand at a compound annual growth rate of 7.2 % from 2024 to 2030, reaching an estimated USD 1.9 billion by the end of the forecast period, offering a robust future outlook for stakeholders, driven by expanding therapeutic pipelines and broader regulatory acceptance.

3. Which factors are driving the market’s expansion?

Key drivers include rising scientific interest in CBG’s neuroprotective and anti‑inflammatory properties, increased funding for cannabinoid research, the need for high‑purity standards in clinical trials, and the growing number of biotech firms incorporating CBG into pipeline candidates.

4. What challenges could hinder market growth?

Challenges comprise limited large‑scale extraction capacity, high production costs for >99 % purity, inconsistent global quality standards, and regulatory uncertainty in jurisdictions where CBG remains classified as a controlled substance, potentially restricting supply chain scalability for manufacturers.

5. Which regions are leading the market?

North America dominates the Reagent Grade CBG market, accounting for over 45 % of global revenue, followed by Europe, where stringent laboratory standards boost demand; emerging growth is observed in Asia‑Pacific, particularly in Japan and South Korea, due to expanding biotech sectors.

6. Who are the top companies operating in this space?

Leading suppliers include GW Pharmaceuticals, Aurora Cannabis, Tilray, PhytoLab, and PureScience, each offering certified‑grade CBG with purity levels above 99 %; these firms differentiate through proprietary extraction technologies, extensive analytical services, and strategic partnerships with research institutions.

7. What future opportunities are emerging for the market?

Future opportunities arise from the development of CBG‑based therapeutics targeting rare neurological disorders, integration of CBG into precision‑medicine platforms, and the rise of contract manufacturing organizations that specialize in producing reagent‑grade cannabinoids for global clinical programs.

8. How is technology influencing the Reagent Grade CBG market?

Advances in supercritical CO₂ extraction, cryogenic distillation, and high‑performance liquid chromatography enable higher yields and consistent >99 % purity, while AI‑driven process optimization reduces waste and lowers costs, accelerating scale‑up for pharmaceutical‑grade applications across multiple production sites.

9. What is the regulatory landscape affecting reagent‑grade CBG?

Regulatory frameworks vary: the US FDA classifies CBG as a research chemical pending IND approval, the EU requires GMP certification for analytical use, while Japan permits limited medical research under strict licensing, creating a patchwork of compliance requirements for global suppliers.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Reagent Grade Cannabigerol (CBG) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	760.64 million
Growth rate	CAGR of 22.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cayman Chemical; LGC Limited; Cambridge Isotope Laboratories, Inc.; Merck KGaA; SPEX CertiPrep; CPI International; Cerilliant Corporation; KND Labs
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options